🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT06453512
Recruiting Not applicable

A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema

NCT06453512 · tracked via the Priya Life Science UK tracker
Sponsor
Dermal Laboratories Ltd
Phase
Not applicable
Started
2024-10-30
Last updated
2025-03-18

Condition(s) studied

Atopic Eczema

Investigational drug(s) / intervention(s)

Doublebase Once

Doublebase Once: Emollient

Study summary

A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.

The study will involve patients who are already using emollients as part of their treatment regime, switching to Doublebase Once. Patients will ideally apply the product once daily for 4 weeks and SCORAD assessments will be performed, and patient questionnaires will be completed. A subgroup of adult patients (up to 15 patients) will also undergo skin hydration measurements for the first 8 days to evaluate objective measurements of skin hydration in patients with atopic eczema.

Photographs of the same, representative area of eczema will also be taken for all patients at baseline and after 4 weeks of using Doublebase Once.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: * ii) Patients with atopic eczema (personal history or combined personal and familial atopy), of any severity in accordance with the NICE categorisation set out in the table below. iii) Baseline SCORAD assessment score of at least 15. iv) Patients or their parents/ legal guardians must be able to read and understand the patient information sheet and sign the Consent Form/Assent Form. v) Patients normally managing their eczema by regular and ongoing use of leave-on emollient(s). vi) Patients who are not currently using systemic or topically applied antibiotics or Doublebase Once. vii) Patients who are willing to use Doublebase Once, once daily, as their only leave-on emollient, for 4 weeks. viii) Patients who are willing to continue to use their standard cleansing regime and/or Doublebase Once as a soap substitute for the duration of the study. Additional inclusion criterion for subgroup for skin hydration assessments: i) Baseline corneometry measurement of ≤40 arbitrary units. Exclusion Criteria: i) Are currently using or have used in the previous month, any systemic or topically applied antibiotics or Doublebase Once for their atopic eczema. ii) Have a known history of intolerance or skin sensitivity to any of the ingredients of Doublebase Once (as identified on the patient information sheet and product labelling), or similar products. iii) Currently participating in any other ongoing research studies or have participated in a study in the previous 30 days. iv) Patients, or their parents/ legal guardians, who may have difficulties completing the questionnaire, which will be written in English only. v) Employees of the Sponsor or Investigators, or any immediate family member (partner, offspring, parents, siblings, or sibling's offspring) of such employees. vi) Patients with any medical condition which, in the opinion of the Investigator, may adversely influence their ability to participate in the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Cripps Medical Centre Nottingham Nottinghamshire Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06453512 on ClinicalTrials.gov ↗ ← All trials in the UK